IntelGenx Technologies Corporation and Cary Pharmaceuticals today announced that the pilot clinical trial of QuitPak showed positive intermediate results.

May 03, 2007

Saint Laurent, Quebec, and Great Falls, Virginia -(CCNMatthews – May 3, 2007) - IntelGenx Technologies Corporation (OTCBB:IGXT)("IntelGenx") and Cary Pharmaceuticals (“Cary”) today announced that the pilot clinical trial of QuitPak (INT003/05) showed positive intermediate results. The plasma profiles of Bupropion and Mecamylamine after administration to 7 of a total of 10 subjects demonstrate that the once-daily formulation meets the study objectives relative to area under the curve (AUC), maximum concentration (Cmax), and Time-to-peak (Tmax) for both components. The 24h pharmacokinetic profile confirms the suitability of the newly developed formulation for once-daily co-administration of Bupropion and Mecamylamine.The complete study results from all 10 subjects are expected to be available soon. The product is intended to address the lucrative $1 bn smoking cessation market. 

“We are very exited about these positive results on INT003/05. The data clearly demonstrate the suitability of our new extended-release formulation for further Phase I and IIb studies that will be conducted later this year. The partnership with Cary Pharmaceuticals represents an important element in the development of our company.” said Dr. Horst Zerbe,CEO of IntelGenx Corp.

“We are very pleased with the results from this first clinical trial involving a product resulting from our development cooperation with Intelgenx. The study represents an important step in our development efforts for a sustained-release formulation for QuitPak® that will be used by the Company to conduct its Pharmacokinetics and Phase IIb clinical trials.” added Doug Cary, CEO of Cary Pharmaceuticals.

IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films.  The company’s research and development pipeline includes products for the treatment of pain management, hypertension, and smoking cessation.

Cary Pharmaceuticals is a pharmaceutical development company. The Company is advancing the development of its two lead products, Tempol, for the treatment of essential hypertension and QuitPak®, for smoking cessation, through Phase IIb clinical trials.

This news release contains certain forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation, statements regarding potential product development and trial results, and the future plans and objectives of Intelgenx are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Intelgenx 's expectations are disclosed elsewhere in documents that are available to the public at


IntelGenx Corp.
Dr. Horst G. Zerbe, President and CEO
President and CEO
T: 514-331-7440 (ext. 201)
F: 514-331-0436

Cary Pharmaceuticals Inc.
Douglas C. Cary, President and CEO
Phone: (703) 771-8540
Fax: (703) 759-6492

The OTCBB has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.